Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
Immunotherapy acquired resistance was observed in clinical practice. The investigators intended to add anlotinib to PD-1 inhibitors, hoping reverse the resistance.
创建时间：
2021-03-15
